Related Experiment Video
Updated: May 9, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
899
Modeling Alzheimer's disease: Bayesian copula graphical model from demographic, cognitive, and neuroimaging data
Lucas Vogels1, Reza Mohammadi1, Marit Schoonhoven1
1Amsterdam Business School, University of Amsterdam, Amsterdam, The Netherlands.
Journal of Alzheimer'S Disease : JAD
|May 5, 2025
Summary
Alzheimer's disease cognition is impacted by aging through brain volume loss and amyloid-beta buildup. Women show a positive cognition correlation, but this is lessened by factors like lower education and brain changes.
Area of Science:
- Neuroscience
- Biostatistics
- Medical Imaging
Background:
- Early Alzheimer's disease (AD) detection necessitates understanding complex feature relationships.
- Conditional independencies and partial correlations are key for identifying confounding and mediating variables in AD.
- Bayesian Gaussian Copula Graphical Models (GCGMs) offer a novel approach for analyzing AD-related data.
Purpose of the Study:
- To estimate conditional dependencies and partial correlations in AD using Bayesian GCGMs.
- To leverage GCGMs' ability to handle diverse data types (binary, discrete, continuous) and quantify uncertainty.
- To apply GCGMs to AD research for the first time.
Main Methods:
- Designed a GCGM to analyze relationships between brain gray matter volume, glucose uptake, amyloid-beta levels, demographics, and cognitive scores.
- Applied the GCGM to a cohort of healthy and cognitively impaired participants across AD stages.
- Utilized Bayesian inference for robust estimation of dependencies and correlations.
Main Results:
- Identified three indirect aging pathways affecting cognition: hippocampal volume loss, posterior cingulate cortex (PCC) volume loss, and amyloid-beta accumulation.
- Found a positive partial correlation between being female and cognition, dampened by lower hippocampal/PCC volume, increased amyloid-beta, and less education.
- Observed limited direct relations for glucose uptake but confirmed hippocampus and PCC volumes are linked to cognition.
Conclusions:
- Bayesian GCGMs provide valuable insights into Alzheimer's disease pathogenesis.
- The study highlights specific neuroanatomical and biological factors influencing cognitive decline in AD.
- Understanding these complex pathways can inform early detection and intervention strategies for AD.
Related Concept Videos
Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
43
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
43
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128

